Row No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	15/NW/0098	138128	A Phase 2, Multicenter, Open-Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, Safety And Activity Of Azacitidine And To Compare Azacitidine To Historical Controls In Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Synd	Number Agreed	1	1	Date Agreed	31/03/2017	0	12/09/2017	0	Recruitment Finished
2	15/NW/0229	170151	Worldwide Randomized Antibiotic Envelope Infection Prevention Trial	Range Agreed	30	100	Date Agreed	30/06/2018	52	25/07/2017	52	Recruitment Finished
3	15/LO/0528	174833	Evaluating the use of wearable technology and smart phone apps to monitor paediatric diseases	Range Agreed	5	10	Date Agreed	01/06/2017	23	31/07/2017	26	Recruitment Finished
4	16/SC/0039	188354	A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis	Range Agreed	2	5	Date Agreed	31/05/2017	0	06/09/2017	0	Recruitment Finished
5	13/LO/1522	137260	LTS13632 (A long-term study to assess the ongoing safety and efficacy of olipudase alfa in patients with acid sphingomyelinase deficiency)	Range Agreed	1	2	Date Agreed	31/08/2017	2	30/08/2017	2	Recruitment Finished
6	17/YH/0083	220358	A Randomized Controlled Trial of Gentle Touch/Early Massage with a New Wash and Lotion Regimen for Improved Skin Barrier Strength, Parental Bonding, and Physical Development in Newborn Babies	Number Agreed	30	30	Date Agreed	30/09/2017	32	30/09/2017	32	Recruitment Finished
7	15/NW/0821	191169	Oricol	Number Agreed	20	20	Date Agreed	31/07/2017	30	21/09/2017	30	Recruitment Finished
8	15/WS/0061	178522	A Randomized, Doubleblind, Eventdriven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and SignificantCoronary Artery Dise	Number Agreed	5	5	Date Agreed	15/10/2017	1	31/07/2017	1	Recruitment Finished
9	15/SC/0456	174561	AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI-PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULTPATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS	Range Agreed	1	3	Date Agreed	30/09/2017	0	29/09/2017	0	Withdrawn By Sponsor
10	16/ES/0001	193859	A Phase 3, randomized, double-blind, placebo-controlled, multicentre study to investigate the efficacy and safety of Mongersen (GED-0301) for the treatment of subjects with active Crohn's Disease	Number Agreed	3	3	Date Agreed	31/03/2017	2	20/10/2017	2	Withdrawn By Sponsor
11	16/WS/0005	193858	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN?S DISEASE	Range Agreed	1	3	Date Agreed	30/11/2017	1	20/10/2017	1	Withdrawn By Sponsor
12	17/SC/0236	226436	PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY	Range Agreed	1	6	Date Agreed	31/12/2017	6	27/11/2017	6	Recruitment Finished
13	16/SC/0542	208245	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITYOF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULARDEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY	Range Agreed	1	4	Date Agreed	31/03/2018	2	20/11/2017	2	Recruitment Finished
14	17/SC/0236	226436	PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY	Number Agreed	1	1	Date Agreed	31/12/2017	1	22/08/2017	1	Recruitment Finished
15	16/ES/0001	193859	Revolve (Celgene GED-0301-CD-002)	Number Agreed	3	3	Date Agreed	29/11/2017	0	19/10/2017	0	Withdrawn By Sponsor
16	17/NW/0019	212375	A3921192 SOAR ? A Study of a Once-A-day investigational drug for RA	Number Agreed	2	2	Date Agreed	21/03/2019	0	31/10/2017	0	Withdrawn By Sponsor
17	13/WM/0235	126333	ATrial FibrillaTion ProgrESsion Trial	Number Agreed	1	1	Date Agreed	01/08/2017	0	27/02/2018	5	Withdrawn By Sponsor
18	13/LO/0867	126972	Double-blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monother	Number Agreed	4	4	Date Agreed	30/03/2018	15	05/01/2018	15	Recruitment Finished
19	15/NW/0698	183781	A twenty six week, randomized, openlabel, 2 arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo? compared to standard of care insulin, in basal insulin treated patients with uncontr	Number Agreed	4	4	Date Agreed	07/10/2016	0	20/12/2017	0	Recruitment Finished
20	17/SC/0016	218645	A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable PleuralMesothelioma	Range Agreed	4	6	Date Agreed	30/06/2018	3	22/02/2018	3	Recruitment Finished

21	14/NI/1038	153733	A Prospective Randomized Controlled Study Evaluating the Safety and Efficacy of EVICEL? used for Suture-Line Sealing in Dura-Mater Closure during Paediatric Neurosurgical Cranial Procedures	Range Agreed	1	6	Date Agreed	01/05/2019	2	05/01/2018	2	Recruitment Finished
22	15/LO/1289	181953	An international, multicenter, randomized, double-blind, placebo-controlledphase 3 trial investigating the efficacy andsafety of Rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheralartery disease	Number Agreed	4	4	Date Agreed	04/09/2017	9	08/12/2017	13	Recruitment Finished
23	15/NW/0827	181796	A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients withRelapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation	Number Agreed	4	4	Date Agreed	28/02/2017	0	20/02/2018	0	Recruitment Finished
24	16/LO/0361	193839	Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults	Number Agreed	4	4	Date Agreed	08/12/2016	7	27/11/2017	7	Recruitment Finished
25	17/NW/0145	217442	Longitudinal study of chronic wounds using novel wound measurement technologies	Range Agreed	10	15	Date Agreed	01/05/2018	16	31/01/2018	16	Recruitment Finished
26	17/NE/0136	224520	A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B	Number Agreed	1	1	Date Agreed	31/10/2017	1	18/10/2017	1	Recruitment Finished
27	16/WM/0170	195010	ISIS 304801-CS7 -An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)	Range Agreed	1	2	Date Agreed	31/12/2017	5	31/12/2017	5	Recruitment Finished
28	17/EM/0044	217658	A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks inpatients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD).	Number Agreed	2	2	Date Agreed	31/05/2018	0	21/02/2018	0	Recruitment Finished
29	14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Number Agreed	50	50	Date Agreed	03/09/2018	116	03/05/2018	116	Recruitment Finished
30	17/SC/0242	222650	A Phase 2A, Randomized, Double-Blind, Placebo- Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction	Number Agreed	4	4	Date Agreed	30/06/2018	2	29/06/2018	2	Recruitment Finished
31	18/YH/0167	246108	A Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered combination of GLPG3067, GLPG2222 and GLPG2737, in adult subjects with cystic fibrosis h	Number Agreed	1	1	Date Agreed	31/12/2050	0	28/06/2018	0	Withdrawn By Sponsor
32	15/WS/0128	168973	A phase 1, first in man, multi-centre, open label, single escalating dose study of BAY 1093884 in subjects with severe Haemophilia types A or B, with or without inhibitors	Range Agreed	1	2	Date Agreed	01/09/2018	1	26/08/2017	1	Recruitment Finished
33	13/NE/0005	100377	A prospective, non-interventional registry providing continuing evaluation and periodic reporting of product safety, effectiveness and patient outcomes across Medtronic market released products within diabetes, cardiac rhythm disorders, urological, gastro	Range Agreed	5	25	Date Agreed	31/07/2019	18	01/08/2017	18	Recruitment Finished
34	16/LO/0803	204170	Study of MiniMed? 640G Insulin Pump with SmartGuard? in prevention of Low Glucose Events in adults with Type 1diabetes	Range Agreed	5	7	Date Agreed	30/09/2017	6	03/04/2018	6	Recruitment Finished
35	16/EM/0436	213166	Single arm study of ALXN1210 in complement inhibitor treatment-naive adult and adolescent patients with atypical hemolytic uremic syndrome (aHUS)	Range Agreed	1	1	Date Agreed	28/02/2018	0	01/06/2018	0	Recruitment Finished
36	17/EE/0026	220207	A Prospective, Randomized, Controlled, Multi-Center Clinical Study of theACRYSOF IQ Extended Depth of Focus (EDF)	Number Agreed	12	12	Date Agreed	30/03/2018	9	06/04/2018	9	Recruitment Finished
37	16/EM/0314	206295	A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-termSafety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus	Number Agreed	3	3	Date Agreed	18/08/2017	1	13/07/2017	1	Recruitment Finished
38	16/WM/0512	218042	A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ferric Maltol at Three Dosage Levels in Paediatric Subjects aged 10-17 years of age with iron deficiency (with or without anae	Range Agreed	3	4	Date Agreed	31/10/2017	2	15/03/2018	4	Recruitment Finished
39	17/LO/1502	232726	An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS443139 in Huntington?s Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139	Range Agreed	1	4	Date Agreed	31/05/2019	4	24/04/2018	4	Recruitment Finished
40	17/SC/0122	224090	AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS)	Range Agreed	4	8	Date Agreed	28/02/2018	8	28/02/2018	8	Recruitment Finished